John Whitesides Selected Research

brivaracetam

1/2020	Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
1/2018	Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program.
1/2018	Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
1/2018	Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
1/2018	A review of the pharmacology and clinical efficacy of brivaracetam.
11/2017	Erratum to "Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study" [Epilepsy Res. 131 (2017) 70-75].
3/2017	Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
1/2017	Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment.
11/2016	Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies.
11/2016	Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Whitesides Research Topics

Disease

12	Seizures (Absence Seizure) 01/2020 - 03/2008
4	Epilepsy (Aura) 01/2020 - 03/2017
4	Parkinson Disease (Parkinson's Disease) 01/2014 - 01/2011
4	Infections 01/2014 - 06/2009
3	Nausea 05/2016 - 01/2011
2	Sleepiness 01/2018 - 01/2014
2	Dizziness (Lightheadedness) 01/2018 - 01/2011
2	Human Influenza (Influenza) 01/2014 - 06/2009
1	Ataxia (Dyssynergia) 01/2018
1	Diplopia (Double Vision) 01/2018
1	Poisoning 01/2018
1	Headache (Headaches) 05/2016
1	Nasopharyngitis 05/2016
1	Fatigue 05/2016
1	Restless Legs Syndrome (Restless Legs) 05/2016
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2014
1	Hallucinations (Hallucination) 01/2014
1	Orthostatic Hypotension (Postural Hypotension) 01/2014
1	Confusion (Bewilderment) 01/2014
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2014
1	Dyskinesias (Dyskinesia) 01/2014
1	Pain (Aches) 09/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 08/2011
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 08/2006

Drug/Important Bio-Agent (IBA)

13	brivaracetamIBA 01/2020 - 12/2015
7	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020 - 11/2016
5	LigandsIBA 01/2018 - 12/2015
5	rotigotine FDA Link 05/2016 - 01/2011
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2014
2	AntibodiesIBA 01/2014 - 06/2009
2	Neutralizing AntibodiesIBA 01/2014 - 08/2011
2	EpitopesIBA 08/2011 - 01/2011
1	Topiramate (Topamax)FDA LinkGeneric 01/2018
1	carbamazepine epoxideIBA 01/2018
1	Lamotrigine (Lamictal)FDA LinkGeneric 01/2018
1	Carbamazepine (Tegretol)FDA LinkGeneric 01/2018
1	Pharmaceutical PreparationsIBA 11/2016
1	Leucine (L-Leucine)FDA Link 01/2014
1	Levodopa (L Dopa)FDA LinkGeneric 01/2014
1	AntigensIBA 01/2014
1	Hemagglutinins (Hemagglutinin)IBA 01/2014
1	Immunoglobulins (Immunoglobulin)IBA 01/2014
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2014
1	Dopamine Agonists (Dopamine Agonist)IBA 08/2011
1	ropinirole (Requip)FDA LinkGeneric 08/2011
1	Monoclonal AntibodiesIBA 08/2011
1	VaccinesIBA 06/2009
1	Lacosamide FDA Link 03/2008
1	C.I. Solvent Yellow 56 (DEAB)IBA 08/2006